Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: Lighthouse who wrote (1352)	2/16/2000 6:28:00 PM
From: Steven Rachbach	Respond to of 3202

Lighthouse, Here is a response about valuations of the genomic companies definitely in the FWIW category: Premise -- The genomic companies of today are the future behemoths of the pharmaceutical industry. Question -- What is the average market cap. of four leading genomic companies compared to four leading pharmaceutical companies of today? Results -- The average market cap. of four leading genomics companies (Millenium, Celera, Human Genome Science and Incyte) is 8 Billion. -- The average market cap of four leading drug companies of today (Merck, Lilly, Warner-Lambert and Pfizer) is over 105 Billion. Discussion -- Obviously, there are many ifs, ands, buts and luck comparing genomic neophytes today with leading established pharmacos. However, with the market caps of the genomic companies less than one-tenth those of today's giants, the genomic stocks may have much more room to run. Regards, Steve